Artemisolide is a typical inhibitor of IκB kinase β targeting cysteine-179 residue and down-regulates NF-κB-dependent TNF-α expression in LPS-activated macrophages

Biochemical and Biophysical Research Communications

Volumn 361, Issue 3, 2007, Pages 593-598

  Kim, Byung Hak ^a   Lee, Jun Young ^a   Seo, Jee Hee ^a   Lee, Hwa Young ^a   Ryu, Shi Yong ^b   Ahn, Byung Woo ^a   Lee, Chong Kil ^a   Hwang, Bang Yeon ^a   Han, Sang Bae ^a   Kim, Youngsoo ^a  

^a Chungbuk National University   (South Korea)

^b Korea Research Institute of Chemical Technology   (South Korea)

Author keywords

Artemisolide; IKK activity; LPS activated macrophages; NF B activation; TNF expression

Indexed keywords

ALANINE; ARTEMISOLIDE; CYSTEINE; HERBACEOUS AGENT; I KAPPA B; I KAPPA B KINASE; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; CELL SURVIVAL; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; ENZYME INHIBITION; IMMUNOREGULATION; MACROPHAGE ACTIVATION; MOLECULAR BIOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ANTI-INFLAMMATORY AGENTS; CYSTEINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; ENZYME INHIBITORS; I-KAPPA B KINASE; LIPOPOLYSACCHARIDES; MACROPHAGES; NF-KAPPA B; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRITERPENES; TUMOR NECROSIS FACTOR-ALPHA;

ARTEMISIA ASIATICA;

EID: 34547754038     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2007.07.069     Document Type: Article

References (22)

1. Olivier S., Robe P., and Bours V. Can NF-κB be a target for novel and efficient anti-cancer agents?. Biochem. Pharmacol. 72 (2006) 1054-1068
2. Beg A.A., Ruben S.M., Scheinman R.I., Haskill S., Rosen C.A., and Baldwin Jr. A.S. IκB interacts with the nuclear localization sequences of the subunits of NF-κB: a mechanism for cytoplasmic retention. Genes Dev. 6 (1992) 1899-1913
3. Karin M., and Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-κB activity. Annu. Rev. Immunol. 18 (2000) 621-663
4. Zandi E., Chen Y., and Karin M. Direct phosphorylation of IκB by IKKα and IKKβ: discrimination between free and NF-κB-bound substrate. Science 281 (1998) 1360-1363
5. Li Z.W., Chu W., Hu Y., Delhase M., Deerinck T., Ellisman M., Johnson R., and Karin M. The IKKβ subunit of IκB kinase (IKK) is essential for nuclear factor κB activation and prevention of apoptosis. J. Exp. Med. 189 (1999) 1839-1845
6. Li Q., Lu Q., Hwang J.Y., Buscher D., Lee K.F., Izpisua-Belmonte J.C., and Verma I.M. IKK1-deficient mice exhibit abnormal development of skin and skeleton. Genes Dev. 13 (1999) 1322-1328
7. Nagai Y., Akashi S., Nagafuku M., Ogata M., Iwakura Y., Akira S., Kitamura T., Kosugi A., Kimoto M., and Miyake K. Essential role of MD-2 in LPS responsiveness and TLR4 distribution. Nat. Immunol. 3 (2002) 667-672
8. Tracey K.J., and Cerami A. Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. Annu. Rev. Med. 45 (1994) 491-503
9. Dhillon S., Lyseng-Williamson K.A., and Scott L.J. Etanercept: a review of its use in the management of rheumatoid arthritis. Drugs 67 (2007) 1211-1241
10. 2 and nitric oxide production in macrophages. Arch. Pharm. Res. 29 (2006) 591-597
11. Jin H.Z., Lee J.H., Lee D., Hong Y.S., Kim Y.H., and Lee J.J. Inhibitors of the LPS-induced NF-κB activation from Artemisia sylvatica. Phytochemistry 65 (2004) 2247-2253
12. Ahn K.Y., Kim B.H., Lee Y.R., Hwang D.H., Chung E.Y., Min K.R., and Kim Y. Dual inhibitory effects of furonaphthoquinone compound on enzyme activity and lipopolysaccharide-induced expression of cyclooxygenase-2 in macrophages. Biochem. Biophys. Res. Commun. 336 (2005) 93-99
13. Shin H.M., Kim M.H., Kim B.H., Jung S.H., Kim Y.S., Park H.J., Hong J.T., Min K.R., and Kim Y. Inhibitory action of novel aromatic diamine compound on lipopolysaccharide-induced nuclear translocation of NF-κB without affecting IκB degradation. FEBS Lett. 571 (2004) 50-54
14. Hehner S.P., Hofmann T.G., Droge W., and Schmitz M.L. The antiinflammatory sesquiterpene lactone parthenolide inhibits NF-κB by targeting the IκB kinase complex. J. Immunol. 163 (1999) 5617-5623
15. 2 inhibits multiple steps in the NF-κB signaling pathway. Proc. Natl. Acad. Sci. USA 97 (2000) 4844-4849
16. Moon K.Y., Hahn B.S., Lee J., and Kim Y.S. A cell-based assay system for monitoring NF-κB activity in human HaCat transfectant cells. Anal. Biochem. 292 (2001) 17-21
17. Baer M., Dillner A., Schwartz R.C., Sedon C., Nedospasov S., and Johnson P.F. Tumor necrosis factor α transcription in macrophages is attenuated by an autocrine factor that preferentially induces NF-κB p50. Mol. Cell. Biol. 18 (1998) 5678-5689
18. Mathas S., Lietz A., Janz M., Hinz M., Jundt F., Scheidereit C., Bommert K., and Dorken B. Inhibition of NF-κB essentially contributes to arsenic-induced apoptosis. Blood 102 (2003) 1028-1034
19. Jeon K.I., Byun M.S., and Jue D.M. Gold compound auranofin inhibits IκB kinase (IKK) by modifying Cys-179 of IKKβ subunit. Exp. Mol. Med. 35 (2003) 61-66
20. Burke J.R., Pattoli M.A., Gregor K.R., Brassil P.J., MacMaster J.F., McIntyre K.W., Yang X., Iotzova V.S., Clarke W., Strnad J., Qiu Y., and Zusi F.C. BMS-345541 is a highly selective inhibitor of IκB kinase that binds at an allosteric site of the enzyme and blocks NF-κB-dependent transcription in mice. J. Biol. Chem. 278 (2003) 1450-1456
21. Castro A.C., Dang L.C., Soucy F., Grenier L., Mazdiyasni H., Hottelet M., Parent L., Pien C., Palombella V., and Adams J. Novel IKK inhibitors: β-carbolines. Bioorg. Med. Chem. Lett. 13 (2003) 2419-2422
22. Goldfeld A.E., McCaffrey P.G., Strominger J.L., and Rao A. Identification of a novel cyclosporin-sensitive element in the human tumor necrosis factor α gene promoter. J. Exp. Med. 178 (1993) 1365-1379